Additional file 4: of A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Figure S4. Proinflammatory cytokines analysis. Plasma levels of pro-inflammatory cytokines (IFN γ, TNFα, IL 2, IL 6, IL 8 IL 10, and IL 12) were not changed significantly by the treatment. (PPTX 189 kb)